Provectus Biopharmaceuticals Reports Publication of Review Paper on PV-10 Tumor Ablation and Immune Stimulation
September 29 2015 - 6:00AM
Business Wire
Journal of Clinical and Cellular Immunology
Publishes Paper Authored by Researchers at University of Illinois
at Chicago
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT,
http://www.pvct.com), a clinical-stage oncology and dermatology
biopharmaceutical company (“Provectus” or the “Company”), today
reported that the Journal of Clinical and Cellular Immunology has
published a paper titled, “The Potential of Intralesional Rose
Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses.” The
paper can be found online at
http://www.omicsonline.org/open-access/the-potential-of-intralesional-rose-bengal-to-stimulate-tcell-mediated-antitumor-responses-2155-9899-1000343.php?aid=59072
Authors Ajay V Maker, Bellur Prabhakar, and Krunal Pardiwala
state that their “article serves to evaluate the potential of
intralesional rose bengal [RB] to stimulate T-cell mediated
anti-tumor responses in in-vitro, pre-clinical, and clinical
studies.” The review covers findings in both animal models and
human clinical trials covering the use of intralesional RB in the
treatment of: melanoma, breast cancer, ovarian cancer, gastric
cancer and sarcoma.
They conclude, “Our current research is establishing the role of
RB in generating anti-tumor immune responses in gastrointestinal
cancer and liver metastases. Decrease in tumor burden and
stimulation of an immune response with PV-10 has been demonstrated
in animal models of metastasis, and correlations of these responses
in clinical studies is consistent with such results. That PV-10
treatment can potentially increase circulating cytotoxic T-cells,
even in patients who were previously treated with immune-activating
checkpoint blockade, supports the possibility that RB induced
cytotoxicity may activate T-cells that are responsible for the
bystander effect on untreated lesions. As such, intralesional
therapy with RB may be a promising new mode of therapy to stimulate
T-cell mediated anti-tumor immune responses.”
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing
oncology and dermatology therapies. PV-10, its novel
investigational drug for cancer, is designed for injection into
solid tumors (intralesional administration), thereby reducing
potential for systemic side effects. Its oncology focus is on
melanoma, breast cancer and cancers of the liver. The Company has
received orphan drug designations from the FDA for its melanoma and
hepatocellular carcinoma indications. PH-10, its topical
investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has
completed Phase 2 trials of PV-10 as a therapy for metastatic
melanoma, and of PH-10 as a topical treatment for atopic dermatitis
and psoriasis. Information about these and the Company’s other
clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information
about Provectus, please visit the Company’s website at www.pvct.com or contact Porter, LeVay & Rose,
Inc.
FORWARD-LOOKING STATEMENTS: This release contains
"forward-looking statements" as defined under U.S. federal
securities laws. These statements reflect management's current
knowledge, assumptions, beliefs, estimates, and expectations and
express management's current views of future performance, results,
and trends and may be identified by their use of terms such as
"anticipate," "believe," "could," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "will," and other similar
terms. Forward-looking statements are subject to a number of risks
and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements.
Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking
statements include those discussed in our filings with the
Securities and Exchange Commission (including those described in
Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2014) and the following:our determination, based on
guidance from the FDA, whether to proceed with or without a partner
with the fully enrolled phase 3 trial of PV-10 to treat locally
advanced cutaneous melanoma and the costs associated with such a
trial if it is necessary to complete (versus interim data
alone);
- our determination whether to license
PV-10, our investigational drug product for melanoma and other
solid tumors such as cancers of the liver, if such licensure is
appropriate considering the timing and structure of such a license,
or to commercialize PV-10 on our own to treat melanoma and other
solid tumors such as cancers of the liver;
- our ability to license PH-10, our
investigational drug product for dermatology, PH-10, on the basis
of our phase 2 atopic dermatitis and psoriasis results, which are
in the process of being further developed in conjunction with
mechanism of action studies; and
- our ability to raise additional capital
if we determine to commercialize PV-10 and/or PH-10 on our own,
although our expectation is to be acquired by a prospective
pharmaceutical or biotech concern prior to commercialization.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150929005513/en/
Provectus Biopharmaceuticals, Inc.Peter R. Culpepper, CFO,
COO866-594-5999 #30orPorter, LeVay & Rose, Inc.Marlon Nurse,
DM, SVP - Investor Relations212-564-4700orTodd Aydelotte - Media
Relations646-428-0644
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024